Navigation Links
Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
Date:5/6/2008

SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire/ -- Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, announced that it has selected CB 813, an improved, second-generation variant of human coagulation factor VIIa, as a development candidate for the treatment of acute bleeding in hemophilia patients. CB 813 was created using Catalyst's proprietary therapeutic protease platform technologies and know-how.

CB 813 is designed to substantially enhance clot-generating activity at the site of bleeding and therefore achieve clinical efficacy with fewer and lower doses than current therapy. In established hemophilia models of acute bleeding, CB 813 has demonstrated a significant improvement in potency compared with the marketed recombinant factor VIIa product, NovoSeven(R) and a competing, second-generation product, NN1731. Catalyst intends to file an Investigational New Drug (IND) application for CB 813 and commence human clinical studies in hemophilia patients in 2009.

"Patients receiving factor VIIa therapy typically require multiple doses of drug and extended treatment times to manage acute bleeding episodes," said Gilbert C. White, II, M.D., Executive Vice President for Research and Director, Blood Research Institute, Blood Center of Wisconsin. "I am excited by the potential shown by CB 813 to improve the efficiency of treatment by achieving a faster onset and an extended duration of therapeutic benefit to patients. These advantages may significantly reduce both the number of doses and treatment time required to manage bleeding and restore normal hemostasis."

"The selection of this development candidate is an exciting milestone for Catalyst. Created to more rapidly and effectively stop bleeding, CB 813 holds great promise as a new agent in the treatment of hemophilia," said Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences. "CB 813 is representat
'/>"/>

SOURCE Catalyst Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
2. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
3. Neurocrine Biosciences Reports First Quarter 2008 Results
4. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
7. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
8. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
9. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... -- Shares of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ) ... results of the Phase 3 Rocket 1 trail of ... to meet its end points, compelling data from the ... studies. An analyst report on AERI that ... analyst summary, valuation, and recommendation can be viewed by ...
(Date:4/30/2015)... Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its first quarter ended March 31, ... quarter of 2015 was $116.2 million, up $14.5 million ... down $5.3 million or 4.4% from the fourth quarter ... as reported in accordance with U.S. generally accepted accounting ...
(Date:4/30/2015)... 30, 2015  Tandem Diabetes Care ® , Inc. (NASDAQ: ... the t:slim ® and t:flex™ Insulin Pumps, today reported ... In comparing the first quarter of 2015 ... 53 percent to $12.3 million from $8.1 million , ... 1,723 pumps "Our investment in resources to build ...
Breaking Medicine Technology:All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27Tandem Diabetes Care Reports First Quarter 2015 Financial Results 2Tandem Diabetes Care Reports First Quarter 2015 Financial Results 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 4Tandem Diabetes Care Reports First Quarter 2015 Financial Results 5Tandem Diabetes Care Reports First Quarter 2015 Financial Results 6
... A new study published online today ... NEJM) shows bevacizumab (Avastin) is as effective as ranibizumab ... treating age-related macular degeneration (AMD). The ... Trials" (CATT) study, a pioneering comparative effectiveness trial made ...
... 2011 PharmaNet Development Group, Inc., a leading provider ... and medical device companies, announced today that Valerie Palumbo ... Quality Assurance. "We are very pleased ... President, PharmaNet Development Group. "Valerie brings deep experience in ...
Cached Medicine Technology:Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration 2Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration 3Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration 4
(Date:5/3/2015)... 03, 2015 Leading international program provider, ... will be awarding the 2015 Harris Wofford Global Service ... Ghebrendrias, are the deserving recipients of the award named ... Harris Llewellyn Wofford. The two recipients were chosen for ... global health. , CFHI is one of seven ...
(Date:5/3/2015)... Missouri (PRWEB) May 03, 2015 ... business that will directly impact your career? The ... designed for dynamic leaders in multinational companies and ... company. In a changing global landscape, differences in ... and relationships. The EMIB program develops the global ...
(Date:5/3/2015)... May 03, 2015 HealthPostures, a ... solutions, announces its appearance at the , May 5 ... that HealthPostures will exhibit at the conference include its ... sit stand solutions is the 6100 TaskMate Executive. Features ... control, an adjustable keyboard tray, extended platform work surface ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 “ ActOn ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... to get connected with organizations to make a difference. , ... are very few things that aren’t about money, which is ...
(Date:5/2/2015)... May 02, 2015 “ Peachtree Audio ... monthly Tech Report, which features the latest and coolest ... expert and special reporter for NewsWatch, conducted the review ... audio equipment. , Music is an important part ... be pampered and given the royal treatment. Peachtree Audio ...
Breaking Medicine News(10 mins):Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2
... vice minister of health in China has sought for more ... organs by patients in their country//. According to him there ... and the actual donations. ,Statistics reveal that 1.5 ... are lucky enough to find organs. In China organs are ...
... come out in support of old wisdom, in order ... health challenges// of today. ,Improving pupil-teacher ... very ethos(institutional culture) of a school will do the ... superiority of aged principles to newer ones such ...
... research conducted by Dr Michael Kisley, a psychologist from the ... more positive// outlook towards life than young people. These findings ... than one hundred and fifty participants took part in this ... neutral and negative aspects of life. The viewing was restricted ...
... on antiretroviral therapy (ART) experience liver enzyme elevation ... advised when prescribing ART in this population. Results ... Antiretrovirals) study indicate that coinfection itself may be ... ,The study investigated whether coinfected individuals on ...
... of AZT, lamivudine, and nevirapine (AZT/3TC/NVP) taken from week ... delivery resulted in significantly reduced HIV levels in breast ... the breast milk of women who were not treated ... Enhancement Against AIDS and Malnutrition) in Mozambique conducted this ...
... The use of medicines to fight cardiovascular disease has been ... past several decades,// as combinations of interventions and medicinal therapy ... ,Two studies has looked at the measurable impact of ... demonstrates that lower doses of therapies may prove to be ...
Cached Medicine News:Health News:'School Sermons' Need a Comeback 2Health News:Study Attributes Elevated Liver Enzymes in HIV/hepatitis to Coinfection Rather Than Antiretrovirals 2Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 2Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 3Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 4Health News:Low-dose Aspirin Beats High-dose After Cardiac Surgery 2Health News:Low-dose Aspirin Beats High-dose After Cardiac Surgery 3
Titanium. Curved shafts with 5.5 mm tying platform. Round knurled handle with dull finish. Overall length 4.3 inches....
Ultra-fine 5 mm tying platform is valuable when manipulating delicate 10-0 and 11-0 sutures. Pin in handle keeps tips in alignment. Shafts available straight or angled 45 degrees, 8 mm from tip. Stra...
Angled 45 degree shafts with tying platform. Wide serrated handle with dull finish. Overall length 4.2 inches....
Ultra-fine tying platform with round knurled handle for fingertip rotational control. Curved shafts. Overall length 3.9 inches....
Medicine Products: